Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1α

Jieru Han, Wenhao Li, Guangyu Shi, Yunlei Huang, Xutao Sun, Na Sun, and Deyou Jiang

1Department of Synopsis of the Golden Chamber, School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China
2Department of Ultrasound Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China
3Fundamental Training Base, Air Force Aviation University, Changchun, Jilin 130021, China
4Department of Typhoid, School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China
5School of Basic Medical Sciences, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang 150040, China

Correspondence should be addressed to Deyou Jiang; jiangdeyouh@163.com

Jieru Han and Wenhao Li contributed equally to this work.

Received 29 July 2021; Accepted 23 February 2022; Published 8 April 2022

Academic Editor: Qingdong Guan

Copyright © 2022 Jieru Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ulcerative colitis (UC) is a complex inflammatory bowel disease (IBD) associated with mitochondrial function. Atractylenolide III (AT III) is a natural product with anti-inflammatory effects. The aim of this work is to investigate the protective effect of AT III on UC and its underlying mechanisms. Herein, dextran sulfate sodium- (DSS-) induced mice and lipopolysaccharide- (LPS-) stimulated intestinal epithelial cells (IEC-6) were employed to mimic UC pathologies in vivo and in vitro. The results showed that in DSS-induced mice, AT III significantly reversed the body weight loss, colon length reduction, disease activity index (DAI) increase, and histological damage. The production of proinflammatory factors and reduction of antioxidants in colitis were suppressed by AT III. In addition, we demonstrated that AT III attenuated the intestinal epithelial barrier destruction and mitochondrial dysfunction induced by DSS, which was similar to the in vitro results in LPS-treated IEC-6 cells. The protein levels of p-AMPK, SIRT1, and PGC-1α along with acetylated PGC-1α were also upregulated by AT III in vivo and in vitro. In conclusion, these findings support that AT III may protect against mitochondrial dysfunction by the activation of the AMPK/SIRT1/PGC-1α signaling pathway during UC development.

1. Introduction

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD) associated with mitochondrial function. Atractylenolide III (AT III) is a natural product with anti-inflammatory effects. The aim of this work is to investigate the protective effect of AT III on UC and its underlying mechanisms. Herein, dextran sulfate sodium- (DSS-) induced mice and lipopolysaccharide- (LPS-) stimulated intestinal epithelial cells (IEC-6) were employed to mimic UC pathologies in vivo and in vitro. The results showed that in DSS-induced mice, AT III significantly reversed the body weight loss, colon length reduction, disease activity index (DAI) increase, and histological damage. The production of proinflammatory factors and reduction of antioxidants in colitis were suppressed by AT III. In addition, we demonstrated that AT III attenuated the intestinal epithelial barrier destruction and mitochondrial dysfunction induced by DSS, which was similar to the in vitro results in LPS-treated IEC-6 cells. The protein levels of p-AMPK, SIRT1, and PGC-1α along with acetylated PGC-1α were also upregulated by AT III in vivo and in vitro. In conclusion, these findings support that AT III may protect against mitochondrial dysfunction by the activation of the AMPK/SIRT1/PGC-1α signaling pathway during UC development.

It is demonstrated that mitochondrial changes are critical hubs of cellular physiology during UC development [4]. For example, mitochondrial ultrastructural disruption and replication reduction are revealed in the lesions of UC [5, 6]. Mitochondrial electron transport chain complex activities are also altered in UC patients or mouse model [7, 8]. In addition, accumulating evidence suggests that epithelial barrier dysfunction might be attributed to mitochondrial abnormalities in colitis [9]. Ho et al. demonstrate that loss
of MDR1 results in mitochondrial impairment along with increased mROS production driving epithelial barrier dysfunction in colitis [10]. It is well known that proliferator-activated receptor-γ coactivator 1-α (PGC-1α) is a key regulator of mitochondrial biogenesis and function [11]. Decreased PGC-1α in the intestinal epithelium of UC caused significant mitochondrial impairment, epithelial barrier damage, and inflammation [12]. Thus, it is necessary to illustrate the role of mitochondrial function in colitis development.

Atractylenolide III (AT III) is one of the main bioactive compounds from the root extracts of Atractylodes macrocephala Koidz, which has anti-inflammatory, neuroprotective, and gastroprotective properties [13–15]. Several studies show that AT III suppresses the production of TNF-α, iNOS, and IL-6 [16, 17]. Song et al. demonstrate that AT III maintains energy metabolism of skeletal muscle cells to protect against obesity and T2DM [18]. In addition, AT III is also reported to inhibit microglial mitochondrial fission in ischemic injury [19]. However, whether AT III protects against UC progression is unclear.

Dextran sodium sulfate- (DSS-) induced mouse is considered an ideal model due to its similarity to human UC in terms of physiology, anatomy, and immune system [20]. Lipopolysaccharide (LPS) is a known inducer of intestinal epithelial barrier dysfunction [21, 22]. Therefore, this present study was designed to explore the potential effects of AT III on experimental colitis and underlying mechanisms using DSS-induced mice in vivo and LPS-stimulated IEC-6 cells in vitro.

2. Materials and Methods

2.1. Animals. All animals were cared in compliance with the Guide for the Care and Use of Laboratory Animals. Ethical approval was obtained from the Animal Experimental Ethics Committee of the First Affiliated Hospital, Heilongjiang University of Chinese Medicine.

Eight-week-old C57BL/6j male mice (20-23 g) were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China) and maintained in standard laboratory conditions with a 12 h light/dark cycle at 22 ± 1 °C with 45-55% humidity. All mice had free access to obtain standard murine chow diet and sterile water. At the initiation of experiments, five mice in each cage were housed and adaptively fed for a week.

2.2. Induction of the UC Animal Model. Mice were randomly separated into five groups: control group, DSS group, DSS+SASP group, DSS+AT III (L) group, and DSS+AT III (H) group. In brief, mice received 3% DSS (160110, MP Biologicals, Santa Ana, CA, USA) in drinking water for 7 consecutive days to establish UC models. For drug administration, DSS mice were injected with 5 mg/kg or 10 mg/kg AT III (A2987, Sigma-Aldrich, St. Louis, MO, USA) through the tail vein once a day for 7 days. Furthermore, mice in the DSS+SASP group were administrated with 200 mg/kg/day sulfasalazine (SASP; S129986, Aladdin, Shanghai, China) orally for 7 consecutive days. SASP was used as a positive control drug. Control mice received the same amount of water without DSS.

During the experiments, the bedding materials of all cages were changed simultaneously to minimize the effect of environmental factors. All animals were weighed and monitored for health signs daily. Also, stool consistency and rectal bleeding were recorded to evaluate the disease activity index (DAI) scores as described previously [23]. Finally, mice (n = 12 per group) were sacrificed by using 150 mg/kg pentobarbital sodium intraperitoneally, and colons were harvested for further investigations.

| Name          | Sequences                     | Product length (bp) |
|---------------|-------------------------------|---------------------|
| MUS TNF-α F   | CAGCGGTTGCTATGCTCA            | 182                 |
| MUS TNF-α R   | GCTCCTCCATGTTGTTT            | 212                 |
| MUS IL-6 F    | ATGGCAATCCATGTTGATG          | 100                 |
| MUS IL-6 R    | GACTCTGGGTTGCTTTCT           | 125                 |
| MUS COX-2 F   | AACACCTGGTCGATGTA            | 155                 |
| MUS COX-2 R   | TTGAGGGAACAGATGGGAAT         | 81                  |
| MUS iNOS F    | TTGGAGGAGTTGTTGGAATG         | 105                 |
| MUS β-actin F | ATGGATGTCAGCGAAGATTTCC       | 62                  |
| MUS β-actin R | GGGCGAGCAAACATACTG           | 81                  |
| MUS mtDNA F   | CTTGACGCTATGTTGATG           | 105                 |
| MUS β-globin F| AACACAAAGGTATGAGC            | 81                  |
| MUS β-globin R| TTGAATCAGCTAAGCATT           | 155                 |
| RAT mtDNA F   | CACACAAAGGTATGAGC            | 81                  |
| RAT mtDNA R   | TTGAATCAGCTAAGCATT           | 155                 |
| RAT β-globin F| CAGTACTTTAAGTTGAAACG         | 81                  |
| RAT β-globin R| ATCAACATAATTGCGAGC           | 155                 |

Table 1: Primer sequences of targeted genes.
2.3. Hematoxylin-Eosin (H&E) Staining. Colons from mice were fixed in 4% paraformaldehyde, embedded in paraffin, and then cut into 5 μm thick sections. The sections were stained with hematoxylin (H8070, Solarbio, Beijing, China) for 5 min and eosin (A600190, Sangon, Shanghai, China) for 3 min. Images were observed under a microscope (BX53, Olympus, Tokyo, Japan) at 100x magnification. The histological scores were assessed blindly to evaluate the level of colitis as described by Banerjee et al. [24].

2.4. Immunohistochemistry. An immunohistochemistry assay was carried out with paraffin sections as mentioned above. The deparaffinized sections were rehydrated in ethanol and heated in citrate buffer for 10 min for antigen retrieval. After blocking in goat serum (SL038, Solarbio) for 15 min at room temperature, the sections were probed with the primary antibody against myeloperoxidase (MPO; 1:50, A1374, ABclonal, Wuhan, China) at 4°C overnight, followed by the secondary antibody (1:500, #31460, Thermo Fisher, Pittsburgh, PA, USA) incubation for 60 min at 37°C. Slices were cultured in DAB reagent and counterstained with hematoxylin. Finally, tissue sections were viewed on a microscope at 400x magnification.

2.5. Determination of MDA and GSH Content and SOD Activity. Proteins from homogenized colonic tissues were quantified using a BCA protein assay kit (P0009, Beyotime, Shanghai, China) and prepared to determine the concentration of malondialdehyde (MDA; A003-1, Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and glutathione (GSH; A006-2, Nanjing Jiancheng Bioengineering Institute), as well as the activity of superoxide dismutase (SOD; A001-1, Nanjing Jiancheng Bioengineering Institute).

2.6. Cell Culture and Treatment. Rat intestinal epithelial cell line IEC-6 cells (Zhong Qiao Xin Zhou Biotechnology Co.,
Figure 2: Continued.
Figure 2: AT III ameliorates DSS-induced inflammation and oxidative stress. (a, b) H&E staining of colon tissues and quantification of histological scores. Scale bar: 200 μm. (c) Immunohistochemical detection of MPO in colons. Scale bar: 50 μm. (d–g) qPCR results of TNF-α, IL-6, COX-2, and iNOS mRNA in colons. (h–j) ELISA measurements of MDA and GSH content, as well as SOD activity. $p < 0.05$, compared to control; $^\& p < 0.05$, compared to DSS.
**Figure 3:** AT III inhibits DSS-induced intestinal barrier impairment. (a, b) Western blots for occludin and ZO-1 proteins and quantification results. (c, d) Representative immunofluorescent images for occludin and quantification results. (e, f) Representative immunofluorescent images for ZO-1 and quantification results. Scale bar: 50 μm.
Figure 4: Continued.
Figure 4: Continued.
2.10. Immunoassay and complex IV activity assay kit (BC0940, Solarbio). The activity of mitochondrial electron transport enzymes was measured using the complex I activity assay kit (BC0510, Solarbio).

2.9. Determination of Complex I and Complex IV Activity. The colon tissues or IEC-6 cells were used to assess the activity of Complexes I and IV. In brief, cells were incubated with 0.5 ml JC-1 staining working solution (C2006, Beyotime) for 20 min. After washing in JC-1 buffer (1×), cells were collected to measure MMP using a flow cytometer (NayoCyte, Aceabio, San Diego, CA, USA).

2.8. JC-1 Assay. The mitochondrial membrane potential (MMP) of IEC-6 cells was determined using the JC-1 (5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarboxyanine iodide) assay. In brief, IEC-6 cells were incubated with 0.5 ml JC-1 staining working solution (C2006, Beyotime) at 37°C for 20 min. After washing in JC-1 buffer (1×), cells were collected to measure MMP using a flow cytometer (NayoCyte, Aceabio, San Diego, CA, USA).

2.7. Intestinal Permeability Assay. For the in vitro permeability assay, cells were seeded in the upper chamber at the density of 5 × 10^5 per well. After treatment, IEC-6 cell monolayers were cultured in 1 ml of FITC-dextran 20 (FD20, TdB Labs, Uppsala, Sweden). The solution (100 μl) was collected from the basal chamber at 60, 120, 180, or 240 min, respectively, and the fluorescent intensity was measured.

2.6. Acetylated PGC-1α. Acetylated PGC-1α expression was determined using Western blot. The acetylated levels of PGC-1α and quantification results were measured. *p < 0.05, compared to control; **p < 0.05, compared to DSS.

2.5. Determination of Gastrointestinal Epithelial Cell Damage. Intestinal epithelial cell damage in UC. In addition, IEC-6 monolayers were cultured in 1 mg/ml FITC-dextran 20 (FD20, TdB Labs, Uppsala, Sweden). The solution (100 μl) was collected from the basal chamber at 60, 120, 180, or 240 min, respectively, and the fluorescent intensity was measured. *p < 0.05, compared to control; **p < 0.05, compared to DSS.

2.4. Determination of Mitochondrial DNA. Mitochondrial DNA (mtDNA) was determined by qPCR analysis. Relative expression of mtDNA was calculated using the 2^-ΔΔCT method and measured by the ratio of mRNA to β-actin. Primer sequences are listed in Table 1.

2.3. Western Blot. Whole cell lysates were extracted using the RIPA lystate (P0013B, Beyotime) and quantified with a BCA protein assay kit. Equal amounts of protein samples were separated by SDS-PAGE and transferred onto the PVDF membrane. After blocking in 5% BSA, membranes were incubated with primary antibodies against PGC-1α (1 : 200; A0562, Beyotime) or Cy3-labeled goat anti-rabbit IgG antibody (1 : 200; A0516, Beyotime) was used to label tissue sections or cell slides at room temperature. After staining with DAPI (D106471, Aladdin), tissue sections or cell slides were observed using the microscope.

2.2. Quantitative Real-Time PCR. Total RNAs in cells or colonic tissues were isolated using the RNA simple total RNA kit (RP1201, BioTeke, Beijing, China) and quantified with Nano 2000 (Thermo Fisher). Then, the Super M-MLV Reverse Transcriptase (2641A, Takara, Beijing, China) was used to transcribe RNAs reversely into cDNAs. The quantitative real-time PCR (qPCR) analysis was carried out on an Exicycler™ 96 instrument (BIONEER, Daejeon, Korea) using the SYBR Green reagent (EP1641A, Takara, Beijing, China). Relative expression of mRNA was calculated using the 2^-ΔΔCT method and measured by the ratio of mRNA to β-actin. Primer sequences are listed in Table 1.
Figure 5: Continued.
were incubated with primary antibodies overnight at 4°C. Subsequently, immunoblots were incubated with secondary antibodies for 40 min at 37°C and visualized using Western ECL Substrate (E003, 7 Sea Biotech, Shanghai, China). All antibodies were as follows: Occludin (1:1000; A2601, ABclonal), ZO-1 (1:1000; A0659, ABclonal), PGC-1α (1:1000; A17089, ABclonal), NRF-1 (1:1000; A5547, ABclonal), NRF-2 (1:1000; A0674, ABclonal), T�am (1:1000; A13552, ABclonal), AMPK (1:1000; AF6423, Affinity), p-AMPK (1:1000; AF3423, Affinity), SIRT1 (1:1000; A11267, ABclonal), β-actin (1:2000; 60008-1-Ig, Proteintech, Wuhan, China), goat anti-mouse IgG antibody (1:10000; SA00001-1, Proteintech), and goat anti-rabbit IgG antibody (1:10000; SA00001-2, Proteintech).

2.14. Immunoprecipitation Assay. The extracted proteins were incubated with 1 μg PGC-1α antibody (sc-518025, Santa Cruz, USA) overnight at 4°C and then incubated with Protein A Agarose beads at 4°C for 2 h. After that, the immunoprecipitates were collected and subjected to SDS-PAGE for further Western blot analysis with specific antibodies: acetyl lysine antibody (1:1000; DF7729, Affinity) and PGC-1α antibody (1:1000; A17089, ABclonal).

2.15. Statistical Analysis. Data were expressed as mean ± standard deviation (SD) and analyzed by using GraphPad Prism 8.0. One-way or two-way repeated analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test was used to assess the statistical significance among multiple groups. The difference among the groups for the histological score was determined using the Kruskal-Wallis test following Dunn’s multiple comparison test. $p < 0.05$ was considered statistically significant.

3. Results

3.1. AT III Protects against DSS-Induced UC in Mice. DSS-induced mice were established to explore the effect of AT
Figure 6: Continued.
Figure 6: AT III attenuates LPS-induced mitochondrial dysfunction in IEC-6 cells via AMPK/SIRT1-mediated deacetylation of PGC-1α. (a) The levels of mtDNA were examined by qPCR. (b) The MMP changes were measured and quantified by the flow cytometry assay using JC-1 probes. (c, d) The complex I and complex IV activities were measured. (e, f) The protein expression levels of PGC-1α, NRF-1, NRF-2, and Tfam were detected and quantified by Western blot. (g, h) The protein expression levels of p-AMPK, AMPK, and SIRT1 were examined and quantified by Western blot. (i, j) The acetylated levels of PGC-1α and quantification results were determined. *p < 0.05, compared to control; &p < 0.05, compared to LPS.
III on UC. As shown in Figure 1(a), mice challenged with DSS exhibited significant increase in DAI scores from the 3rd day, which was recovered by AT III or SASP treatment. Administration of AT III or SASP also reversed the reduction of body weight and colon length caused by DSS (Figures 1(b)–1(d)). The mitigated rectal bleeding was observed in UC mice treated with AT III or SASP from the macroscopical images of colons (Figure 1(c)). These results indicate the beneficial effect of AT III on UC progression.

3.2. AT III Ameliorates DSS-Induced Inflammation and Oxidative Stress. Inflammation and oxidative stress are major pathological changes in UC. Histological results demonstrated that AT III or SASP treatment significantly alleviated the crypt damage, inflammatory cell infiltration, and goblet cell loss in colons of DSS-treated mice (Figures 2(a) and 2(b)). The MPO levels in colon tissues of UC mice were also reduced by AT III or SASP, which are shown in Figure 2(c). In addition, we noticed that the AT III or SASP treatment significantly inhibited the upregulation of proinflammatory factors in colons of UC mice, including TNF-α, IL-6, COX-2, and iNOS (Figures 2(d)–2(g)). The increase in MDA levels, reduction of GSH concentration, and inactivation of SOD activity in colons of DSS-treated mice were also significantly reversed by AT III or SASP (Figures 2(h)–2(j)). Thus, the data suggest that AT III might attenuate the inflammation and oxidative stress in UC development.

3.3. AT III Inhibits DSS-Induced Intestinal Barrier Impairment. Considering that epithelial barrier damage is an essential event during UC development, we focused on investigating the effects of AT III on the intestinal epithelium. Western blot results showed that the decreased protein levels of occludin and ZO-1 in colons of UC mice were reversed by AT III or SASP (Figures 3(a) and 3(b)). Similar changes for occludin and ZO-1 in colons were also demonstrated by the immunofluorescence staining assay (Figures 3(c)–3(f)). It indicates the protective effect of AT III on intestinal barrier destruction in UC.

3.4. AT III Attenuates DSS-Induced Mitochondrial Dysfunction via AMPK/SIRT1-Mediated Deacetylation of PGC-1α. Mitochondrial dysfunction is a critical contributor to inflammation, oxidative stress, and barrier destruction. Thus, the effect of AT III on mitochondrial dysfunction in UC is focused in this study. The results showed that AT III treatment significantly upregulated the number of mtDNA copies and the activities of complex I and complex IV in colons of UC mice (Figures 4(a)–4(c)). The mitochondrial outer membrane protein Tom20 was also increased by AT III (Figures 4(d) and 4(e)). In addition, we observed that AT III significantly reversed the decreased expressions of mitochondrial-related proteins in colons of UC mice, including PGC-1α, NRF-1, NRF-2, and Tfam (Figures 4(f) and 4(g)). The AMPK/SIRT1 signaling pathway is found to be the upstream of PGC-1α, and SIRT1 activates PGC-1α through NAD⁺-dependent deacetylation. However, whether the AMPK/SIRT1 signaling pathway mediates the effect of AT III on mitochondrial function is unclear. We demonstrated that the reduction in p-AMPK and SIRT1 protein levels in colons of DSS-treated mice was reversed by AT III (Figures 4(h) and 4(i)). In addition, AT III inhibited DSS-induced acetylation of PGC-1α in colons (Figures 4(j) and 4(k)). These results indicate that AT III attenuates...
mitochondrial dysfunction by activating AMPK/SIRT1-mediated deacetylation of PGC-1α to protect against UC.

3.5. AT III Abrogates LPS-Induced Intestinal Barrier Impairment in IEC-6 Cells. To further explore the effect of AT III on epithelial barrier function, LPS-treated IEC-6 cells were employed as an in vitro model. As shown in Figure 5(a), AT III effectively recovered the high cell permeability in LPS-stimulated IEC-6 cells. The levels of occludin and ZO-1 proteins in LPS-treated cells were increased by AT III treatment, as evidenced by both Western blot analysis (Figures 5(b) and 5(c)) and immunofluorescence staining results (Figures 5(d)–5(g)). These in vitro experiments confirm that AT III mitigates intestinal epithelial barrier damage induced by LPS.

3.6. AT III Attenuates LPS-Induced Mitochondrial Dysfunction in IEC-6 Cells via AMPK/SIRT1-Mediated Deacetylation of PGC-1α. To assess the underlying mechanisms of AT III in the regulation of epithelial barrier function, mitochondrial function was further investigated in vitro. Similar to the alterations in vivo, decreased mtDNA copy number in LPS-treated cells was reversed by AT III (Figure 6(a)). The JC-1 staining assay showed that AT III reversed LPS-induced decrease in MMP in IEC-6 cells (Figure 6(b)). The reduction of electron transport chain complex activities and decreased expression of mitochondrial proteins in LPS-treated IEC-6 cells were also upregulated by AT III (Figures 6(c)–6(f)). In addition, we suggested that AT III significantly activated p-AMPK and SIRT1 protein levels and deacetylated PGC-1α in LPS-treated cells (Figures 6(g)–6(j)). Thus, these data imply that AT III might activate AMPK/SIRT1-mediated deacetylation of PGC-1α to attenuate mitochondrial dysfunction of intestinal epithelial cells, which has been summarized in Figure 7.

4. Discussion

Although a number of therapeutics are available for the treatment of IBD in a clinical setting, the significant side effects are heavy burden on the quality of life. Thus, this study was aimed at exploring a potential drug for the treatment of UC. Our results showed that AT III mitigated colitis symptoms, inhibited inflammation and oxidative stress, and restored epithelial barrier destruction in colons of UC mice. Experiments in vivo and in vitro suggested that AT III protected against mitochondrial dysfunction of the intestinal epithelium through the activation of AMPK/SIRT1/PGC-1α.

Inflammatory responses and oxidative stress are known to be important features of UC pathogenesis [25, 26]. The proinflammatory cytokines (such as TNF-α, IL-1β, and IL-6) and proteins (such as iNOS and COX-2) are important mediators of the inflammatory process in UC [27, 28]. MPO production is a key biomarker of activated neutrophils in IBD and is associated with oxidative stress [29]. Several reports showed that AT III suppressed the expression levels of proinflammatory factors (TNF-α, IL-6, and IL-1β) and oxidative stress factors (SOD and MDA) in vivo and in vitro [19, 30]. Consistent with these findings, our results demonstrated that AT III suppressed the inflammation and oxidative stress in colons of UC, suggesting a protective effect of AT III on experimental colitis.

Impaired structural and functional integrity of the epithelial barrier is discovered to exacerbate the intestinal inflammatory response and is correlated with the expression of tight junction proteins (including ZO-1 and occludin) [31–33]. In DSS-induced colitis mice, the significant intestinal barrier disruption and mucosal hyperpermeability were observed [34, 35]. Bein et al. also reported that LPS was a commonly used stimulator to cause hyperpermeability and barrier destruction in intestinal inflammatory disorders [36]. In this study, we found that AT III increased low levels of tight junction proteins and reduced hyperpermeability in vivo and in vitro. Thus, it indicates that the protective effect of AT III in colitis might be attributed to maintaining the barrier function of the intestinal epithelium.

Mitochondria are intracellular double-membrane-bound organelles that play a key role in inflammatory diseases such as rheumatoid arthritis and UC [37, 38]. The maintenance of mitochondrial function might counteract the inflammation, oxidative stress, and epithelial barrier damage in colitis [39, 40]. The in vitro experiments showed that LPS might lead to the significant intestinal injury and mitochondrial dysfunction [22]. However, whether mitochondrial function is regulated by AT III in the protection of the intestinal epithelial barrier remains unclear. Our results suggested that AT III attenuated mitochondrial dysfunction in colons of DSS-induced mice, which was similar to the results in LPS-treated IEC-6 cells. This finding was consistent with the finding that AT III suppressed mitochondrial dysfunction in microglia reported by Zhou et al. [19]. Interestingly, Boyapati et al. revealed an increased level of mtDNA in the plasma of UC patients [41], which was contrary to our results in vivo and in vitro. One possible explanation might be that during the severe tissue or cell injury, massive amounts of mtDNAs were released into the circulating plasma and exacerbated the inflammatory diseases. Although AT III has been shown to attenuate epithelial barrier disruption through maintaining mitochondrial function, its potential pathway still requires more investigations.

PGC-1α, an important regulator of mitochondrial bio genesis and function, has been shown to interact with nuclear respiration factors (NRF-1 and NRF-2) to activate T�am in mtDNA replication/transcription [42, 43]. In addition, PGC-1α might be activated by AMPK and SIRT1 and deacetylated by SIRT1 in a NAD+ dependent manner [44, 45]. In experimental colitis, the enhanced PGC-1α deacetylation was shown to repair damaged mitochondria and maintain intestinal barrier function [12]. Our in vivo and in vitro results suggested that AT III increased PGC-1α expression and promoted its deacetylation through the activation of AMPK/SIRT1, which was in accord with the reports in skeletal muscle cells by Song et al. [18]. Altogether, it indicates that AMPK/SIRT1/PGC-1α may be a potential pathway mediating the protective effect of AT III on mitochondrial dysfunction in the intestinal epithelium of experimental colitis.
To explore the action mechanism of drugs or natural products for UC prevention or treatment, many chemicals are widely accepted to induce UC models, such as DSS, 2,4,6-trinitrobenzenesulfonic acid (TNBS), and oxazolone (OXA) [46]. In particular, DSS is the most common chemical for UC induction due to its availability, practicality, and reproducibility, and it is most similar to human UC in terms of clinical, histological, and immunophysiological aspects [47]. Due to the complex etiologies of UC, one of the limitations of this study is that DSS-induced experimental colitis does not fully cover the pathology of human UC. More experimental models will be used in the future to investigate the effect of AT III in UC and its mechanisms.

In conclusion, this present work suggests that AT III protects against mitochondrial dysfunction and ameliorates colitis development by the activation of the AMPK/SIRT1/PGC-1α signaling pathway, which is summarized in Figure 7. It highlights an important role of AT III for the treatment of UC.

Data Availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Conflicts of Interest

All the authors declare no conflict of interest.

Authors’ Contributions

Jieru Han and Wenhao Li contributed equally to this work.

Acknowledgments

This study was supported by a grant from the National Natural Science Foundation of China (No. 81704055).

References

[1] T. A. Malik, "Inflammatory bowel disease: historical perspective, epidemiology, and risk factors," The Surgical Clinics of North America, vol. 95, no. 6, pp. xi–xii, 2015.
[2] H. S. P. de Souza and C. Fiocchi, "Immunopathogenesis of IBD: current state of the art," Gastroenterology & Hepatology, vol. 13, no. 1, pp. 13–27, 2016.
[3] D. C. Baumgart and W. J. Sandborn, "Inflammatory bowel disease: clinical aspects and established and evolving therapies," Lancet, vol. 369, no. 9573, pp. 1641–1657, 2007.
[4] P. McQueen, K. Busman-Sahay, F. Rieder et al., "Intestinal proteomic analysis of a novel non-human primate model of experimental colitis reveals signatures of mitochondrial and metabolic dysfunction," Mucosal Immunology, vol. 12, no. 6, pp. 1327–1335, 2019.
[5] S.-Y. Hsieh, T. C. Shih, C. Y. Yeh, C. J. Lin, Y. Y. Chou, and Y. S. Lee, "Comparative proteomic studies on the pathogenesis of human ulcerative colitis," Proteomics, vol. 6, no. 19, pp. 5322–5331, 2006.
[6] K. Fukushima and C. Fiocchi, "Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients," American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 286, no. 5, pp. G804–G813, 2004.
[7] S. Santhanam, S. Rajamanickam, A. Motamarry et al., "Mitochondrial electron transport chain complex dysfunction in the colonic mucosa in ulcerative colitis," Inflammatory Bowel Diseases, vol. 18, no. 11, pp. 2158–2168, 2012.
[8] K. G. Sifroni, C. R. Damiani, C. Stoffel et al., "Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitis," Molecular and Cellular Biochemistry, vol. 342, no. 1-2, pp. 111–115, 2010.
[9] F. Bär, W. Bochmann, A. Widok et al., "Mitochondrial gene polymorphisms that protect mice from colitis," Gastroenterology, vol. 145, no. 5, pp. 1055–1063.e3, 2013.
[10] G. T. Ho, R. E. Aird, B. Liu et al., "MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation," Mucosal Immunology, vol. 11, no. 1, pp. 120–130, 2018.
[11] P. J. Fernandez-Marcos and J. Auwerx, "Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis," The American Journal of Clinical Nutrition, vol. 93, no. 4, pp. 884S–890S, 2011.
[12] K. E. Cunningham, G. Vincent, C. P. Sodhi et al., "Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC1α) protects against experimental murine colitis," The Journal of Biological Chemistry, vol. 291, no. 19, pp. 10184–10200, 2016.
[13] G.-Q. Ji, R.-Q. Chen, and L. Wang, "Anti-inflammatory activity of atractylenolide III through inhibition of nuclear factor-κB and mitogen-activated protein kinase pathways in mouse macrophages," Immunopharmacology and Immunotoxicology, vol. 38, no. 2, pp. 98–102, 2016.
[14] G. O. Wen-Xia, Z. H. Yu-Zhi, Q. I. Xue-Mei, and D. U. Guang-Hua, "Involvement of mitochondrial apoptotic pathway and MAPKs/NF-κB inflammatory pathway in the neuroprotective effect of atractylenolide III in corticosterone-induced PC12 cells," Chinese Journal of Natural Medicines, vol. 17, no. 4, pp. 264–274, 2019.
[15] K.-T. Wang, L. G. Chen, C. H. Wu, C. C. Chang, and C. C. Wang, "Gastroprotective activity of atractylenolide III from Atractylodes ovata on ethanol-induced gastric ulcer in vitro and in vivo," The Journal of Pharmacy and Pharmacology, vol. 62, no. 3, pp. 381–388, 2010.
[16] T.-H. Kang, N. R. Han, H. M. Kim, and H. J. Jeong, "Blockade of IL-6 secretion pathway by the sesquiterpenoid atractylenolide III," Journal of Natural Products, vol. 74, no. 2, pp. 223–227, 2011.
[17] C.-Q. Li, L.-C. He, and J.-Q. Jin, "Atractylenolide I and atractylenolide III inhibit lipopolysaccharide-induced TNF-alpha and NO production in macrophages," Phytotherapy Research : PTR, vol. 21, no. 4, pp. 347–353, 2007.
[18] M. Y. Song, H. W. Jung, S. Y. Kang, and Y. K. Park, "Atractylenolide III enhances energy metabolism by increasing the SIRT-1 and PGC1α expression with AMPK phosphorylation in C2C12 mouse skeletal muscle cells," Biological & Pharmaceutical Bulletin, vol. 40, no. 3, pp. 339–344, 2017.
[19] K. Zhou, J. Chen, J. Wu et al., "Atractylenolide III ameliorates cerebral ischemic injury and neuroinflammation associated with inhibiting JAK2/STAT3/Drp1-dependent mitochondrial fission in microglia," Phytomedicine, vol. 59, p. 152922, 2019.
[20] D. D. Eichele and K. K. Kharbanda, "Dextran sodium sulfate colitis murine model: an indispensable tool for advancing
our understanding of inflammatory bowel diseases pathogenesis,” *World Journal of Gastroenterology*, vol. 23, no. 33, pp. 6016–6029, 2017.

[21] W.-C. Huang, J. Liang, M. Nagahashi et al., “Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans,” *FASEB Journal*, vol. 30, no. 8, pp. 2945–2958, 2016.

[22] S. Cao, Q. Zhang, C. C. Wang et al., “LPS challenge increased intestinal permeability, disrupted mitochondrial function and triggered mitophagy of piglets,” *Innate Immunology*, vol. 24, no. 4, pp. 221–230, 2018.

[23] S. N. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergren, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” *Digestive Diseases and Sciences*, vol. 38, no. 9, pp. 1722–1734, 1993.

[24] A. Banerjee, D. Bizzaro, P. Burra et al., “Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient mice,” *Stem Cell Research & Therapy*, vol. 6, no. 1, p. 79, 2015.

[25] H. Zhu and Y. R. Li, “Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence,” *Experimental Biology and Medicine*, vol. 237, no. 5, pp. 474–480, 2012.

[26] K. J. Maloy and F. Powrie, “Intestinal homeostasis and its breakdown in inflammatory bowel disease,” *Nature*, vol. 474, no. 7351, pp. 298–306, 2011.

[27] G. Dijkstra, S. Yuvaraj, H. Q. Jiang et al., “Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RB(high) CD4(+) T cells in a model for experimental colitis,” *Inflammatory Bowel Diseases*, vol. 13, no. 12, pp. 1467–1474, 2007.

[28] A. E. V. Quaglio, A. C. S. Castilho, and L. C. Di Stasi, “Experimental evidence of heparanase, Hsp70 and NF-kB gene expression on the response of anti-inflammatory drugs in TNBS-induced colonic inflammation,” *Life Sciences*, vol. 141, pp. 179–187, 2015.

[29] Y. Naito, T. Takagi, and T. Yoshikawa, “Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease,” *Journal of Gastroenterology*, vol. 42, no. 10, pp. 787–798, 2007.

[30] M. Wang et al., “Atractylenolide III attenuates muscle wasting in chronic kidney disease via the oxidative stress-mediated PI3K/AKT/mTOR pathway,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 1875471, 16 pages, 2019.

[31] E. A. Novak and K. P. Mollen, “Mitochondrial dysfunction in inflammatory bowel disease,” *Frontiers in Cell and Development Biology*, vol. 3, p. 62, 2015.

[32] T. Y. Ma, G. K. Iwamoto, N. T. Hoa et al., “TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-kB activation,” *Gastrointestinal and Liver Physiology*, vol. 286, no. 3, pp. G367–G376, 2004.

[33] Q. Y. Lean, N. Gueven, R. D. Eri et al., “Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes,” *Expert Review of Clinical Pharmacology*, vol. 8, no. 6, pp. 795–811, 2015.

[34] M. E. van Meeteren, J. D. van Bergeijk, A. P. M. van Dijk, C. J. A. M. Tak, M. A. C. Meijssen, and F. J. Zijlstra, “Intestinal permeability and contractility in murine colitis,” *Mediators of Inflammation*, vol. 7, 168 pages, 1998.

[35] L. S. Poritz, K. I. Garver, C. Green, L. Fitzpatrick, F. Ruggiero, and W. A. Koltun, “Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis,” *The Journal of Surgical Research*, vol. 140, no. 1, pp. 12–19, 2007.

[36] A. Bein, A. Zilbershtein, M. Golosovsky, D. Davidov, and B. Schwartz, “LPS induces hyper-permeability of intestinal epithelial cells,” *Journal of Cellular Physiology*, vol. 232, no. 2, pp. 381–390, 2017.

[37] L. V. Collins, S. Hajizadeh, E. Holme, I. M. Jonsson, and A. Tarkowski, “Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses,” *Journal of Leukocyte Biology*, vol. 75, no. 6, pp. 995–1000, 2004.

[38] N. M. Shafik, R. A. Gaber, D. A. Mohamed, and A. M. Ebeid, “Hesperidin modulates dextran sulfate sodium-induced ulcerative colitis in rats: targeting sphingosine kinase-1- sphingosine 1 phosphate signaling pathway, mitochondrial biogenesis, inflammation, and apoptosis,” *Journal of Biochemical and Molecular Toxicology*, vol. 33, no. 6, article e22312, 2019.

[39] P. R. Yeganesh, J. Leahy, S. Spahis et al., “Apple peel polyphenols reduce mitochondrial dysfunction in mice with DSS-induced ulcerative colitis,” *The Journal of Nutritional Biochemistry*, vol. 57, pp. 56–66, 2018.

[40] S.-Q. Wang, S.-X. Cui, and X.-J. Qu, “Metformin inhibited colitis and colitis-associated cancer (CAC) through protecting mitochondrial structures of colorectal epithelial cells in mice,” *Cancer Biology & Therapy*, vol. 20, no. 3, pp. 338–348, 2019.

[41] R. K. Boyapati, D. A. Dorward, A. Tamborska et al., “Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern released during active IBD,” *Inflammatory Bowel Diseases*, vol. 24, no. 10, pp. 2113–2122, 2018.

[42] Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1α,” *Cell*, vol. 98, no. 1, pp. 115–124, 1999.

[43] D. Knutti and A. Kralli, “PGC-1α, a versatile coactivator,” Trends in Endocrinology and Metabolism: TEM, vol. 12, no. 8, pp. 360–365, 2001.

[44] H. Zong, J. M. Ren, L. H. Young et al., “AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 25, pp. 15983–15987, 2002.

[45] J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver, “Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1,” *Nature*, vol. 434, no. 7029, pp. 113–118, 2005.

[46] R. D. do Nascimento, A. P. da Fonseca Machado, J. Galvez, C. B. Cazarin, and M. R. Junior, “Ulcerative colitis: gut microbiota, immunopathogenesis and application of natural products in animal models,” *Life Sciences*, vol. 258, p. 118129, 2020.

[47] P. K. Randhawa, K. Singh, N. Singh, and A. S. Jaggi, “A review on chemical-induced inflammatory bowel disease model in rodents,” *The Korean Journal of Physiology & Pharmacology*, vol. 18, no. 4, pp. 279–288, 2014.